Aspen Aerogels, Inc.
NYSE:ASPNConstruction
+$0.24 today
- Market cap
- $407.33M
- Beta
- 2.99
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$1.35
Volume 1.17M
Average 1.58M
ASPN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aspen Aerogels, Inc.NYSE: ASPN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.72M fell 37.1% year over year, behind the -34.0% change in trailing-twelve-month research & development. Sequentially, it fell 2.5% from the prior quarter. Over 3 fiscal years it compounded at +619.1% a year.
Context
- Research & development amounted to 2322.0% of revenue in FY2025, up 2318.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -37.1% toward the trailing-twelve-month pace of -34.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.3B USD
- Year-over-year change
- +34776.1%
- 4-year CAGR
- +384.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.3B | +34776.1% |
| FY2024 | 2024-12-31 | 18.05M | +10.4% |
| FY2023 | 2023-12-31 | 16.36M | -3.4% |
| FY2022 | 2022-12-31 | 16.93M | +48.0% |
| FY2021 | 2021-12-31 | 11.44M | — |
Research & Development vs competitors
How ASPN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -34.0% is the 5th highest of 6, against a peer median of -3.7%.
- Research & development amounts to 5.1% of revenue for ASPN, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CN¥217.38M CNY | +9.3% | +12.9% | 52.1% | |
| LTM Mar 2026 | $38.04M USD | -3.7% | -12.3% | 18.1% | |
| LTM Mar 2026 | $11.81M USD | -34.0% | +619.1% | 5.1% | |
| LTM Mar 2026 | $10.89M USD | +107.8% | +139.6% | — | |
| FY2025 | €8.49M EUR | -5.4% | +70.9% | 26.9% | |
| LTM Feb 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Apr 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ASPN) | — | -3.7% | +41.9% | 0.0% | |
Competitors are the stored peer set for ASPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 121.62M | 180.36M | 238.72M | 452.7M | 271.1M |
| Cost of Revenue | 111.69M | 175.39M | 181.8M | 269.8M | 225.11M |
| Gross Profit | 9.94M | 4.98M | 56.92M | 182.9M | 46M |
| Gross Margin | 8.2% | 2.8% | 23.8% | 40.4% | 17.0% |
| Research & Development | 11.44M | 16.93M | 16.36M | 18.05M | 6.3B |
| Selling, General & Admin | 39.1M | 67.29M | 89.77M | 106.8M | 40.91B |
| Operating Expenses | 50.54M | 84.22M | 106.12M | 128.36M | 97.39M |
| Depreciation & Amortization | 9.44M | 9.22M | 18.18M | 24.41M | 45.16M |
| EBITDA | (27.43M) | (68.41M) | (22.31M) | 51.46M | 5.72B |
| EBITDA Margin | -22.5% | -37.9% | -9.3% | 11.4% | 2108.3% |
| Operating Income | (40.6M) | (79.25M) | (49.2M) | 54.54M | (51.39M) |
| Operating Margin | -33.4% | -43.9% | -20.6% | 12.0% | -19.0% |
| Interest Income | 0 | 1.62M | 6.53M | 0 | 0 |
| Interest Expense | 229K | 5.11M | 5.33M | 11.96M | 6.06B |
| Other Income / Expenses | 3.51M | (3.49M) | 3.39M | (39.45M) | (335.77M) |
| Income Before Tax | (37.09M) | (82.74M) | (45.81M) | 15.09M | (387.16M) |
| Pre-Tax Margin | -30.5% | -45.9% | -19.2% | 3.3% | -142.8% |
| Income Tax Expense | 0 | 0 | 0 | 1.71M | 2.39M |
| Net Income | (37.09M) | (82.74M) | (45.81M) | 13.38M | (389.55M) |
| Net Margin | -30.5% | -45.9% | -19.2% | 3.0% | -143.7% |
| EPS (Basic) | (0.92) | (2.19) | (0.66) | 0.17 | (4.74) |
| EPS (Diluted) | (0.92) | (2.19) | (0.66) | 0.17 | (4.74) |
| Weighted Avg Shares | 30.43M | 39.36M | 69.44M | 77.54M | 82.66M |
| Weighted Avg Shares (Diluted) | 30.43M | 39.36M | 69.44M | 80.31M | 82.66M |
Aspen Aerogels, Inc.
NYSE:ASPN
Intrinsic Alpha fair value
Locked
Current Price
$4.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.